- Home
- GNTA vs ANL Comparison
GNTA vs ANL Comparison
Compare GNTA & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GNTA | ANL |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | Italy | Cayman Islands |
| Employees | N/A | 123 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 293.4M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | GNTA | ANL |
|---|---|---|
| Price | $0.85 | $7.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 53.4K | ★ 215.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $0.88 |
| 52 Week High | $10.00 | $12.09 |
Technical Indicators
Market Signals| Indicator | GNTA | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 47.12 |
| Support Level | $0.71 | $7.21 |
| Resistance Level | $1.70 | $9.98 |
| Average True Range (ATR) | 0.08 | 1.05 |
| MACD | 0.01 | -0.31 |
| Stochastic Oscillator | 17.75 | 25.68 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.